Eticovo Dosage

Generic name: etanercept 25mg in 0.5mL
Dosage form: injection, solution
Drug classes: Antirheumatics, TNF alfa inhibitors

Medically reviewed by Drugs.com. Last updated on Apr 27, 2023.

Adult Patients

Eticovo is administered by subcutaneous injection.

Table 1. Dosing and Administration for Adult Patients
Patient Population	Recommended Dosage Strength and Frequency
Adult RA, AS, and PsA	50 mg weekly
Adult PsO	Starting Dose: 50 mg twice weekly for 3 months Maintenance Dose: 50 mg once weekly

See the Eticovo (etanercept-ykro) “Instructions for Use” insert for detailed information on injection site selection and dose administration [see Dosage and Administration (2.3) and Patient Counseling Information (17)].

Adult Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients

Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with Eticovo.

Based on a study of 50 mg etanercept twice weekly in patients with RA that suggested higher incidence of adverse reactions but similar American College of Rheumatology (ACR) response rates, doses higher than 50 mg per week are not recommended.

Adult Plaque Psoriasis Patients

In addition to the 50 mg twice weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. The proportion of responders was related to etanercept dosage [see Clinical Studies (14.5)].

Pediatric Patients

Eticovo is administered by subcutaneous injection.

Table 2. Dosing and Administration for Pediatric Patients (PsO or JIA)
Pediatric Patients Weight	Recommended Dose
63 kg (138 pounds) or more	50 mg weekly

Note: There is no dosage form for Eticovo that allows weight base dosing for pediatric patients below 63 kg (138 pounds). To achieve pediatric doses other than 50 mg, use other reconstituted etanercept products lyophilized powder.

Doses of etanercept products higher than those described in Table 2 have not been studied in pediatric patients.

In JIA patients, glucocorticoids, NSAIDs, or analgesics may be continued during treatment with Eticovo.

Preparation of Eticovo

Eticovo is intended for use under the guidance and supervision of a physician. Patients may self-inject when deemed appropriate and if they receive medical follow-up, as necessary. Patients should not self-administer until they receive proper training in how to prepare and administer the correct dose. Administer injections subcutaneously in the thigh, abdomen or outer area of the upper arm.

The Eticovo (etanercept-ykro) “Instructions for Use” insert for each presentation contains more detailed instructions on injection site selection and the preparation of Eticovo.

Preparation of Eticovo Single-dose Prefilled Syringe

For a more comfortable injection, leave Eticovo single-dose prefilled syringe at room temperature for at least 30 minutes before injecting. DO NOT remove the needle cover while allowing the prefilled syringe to reach room temperature.

Inspect visually for particulate matter and discoloration prior to administration. There may be small white particles of protein in the solution. This is not unusual for proteinaceous solutions. The solution should not be used if discolored or cloudy, or if foreign particulate matter is present.

Monitoring to Assess Safety

Prior to initiating Eticovo and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection [see Warnings and Precautions (5.1)].